Ustekinumab

Resumen

Alternativas con registro en Colombia

• Basiliximab · costo anual estimado $ 2.583.167.050
• Tocilizumab · costo anual estimado $ 31.120.265
• Canakinumab · costo anual estimado $ 356.878.385
• Secukinumab · costo anual estimado $ 60.543.645
• Ixekizumab · costo anual estimado $ 67.164.015
• Guselkumab · costo anual estimado $ 36.824.485
• Risankizumab · costo anual estimado $ 34.575.720
• Espesolimab
• Mirikizumab

Estudios clínicos principales

• UNIFI: A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colit
  Fase 3 · 2015 · 961 participantes · Janssen Research & Development, LLC · NCT02407236
• A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
  Fase 3 · 2011 · 1.282 participantes · Janssen Research & Development, LLC · NCT01369355
• NAVIGATE: A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to Ustekinumab
  Fase 3 · 2014 · 872 participantes · Janssen Research & Development, LLC · NCT02203032
• A Study to Investigate ABP 654 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
  Fase 3 · 2020 · 563 participantes · Amgen · NCT04607980

Enfermedades relacionadas

• Enfermedad inflamatoria intestinal (Crohn, colitis)
• Psoriasis y artritis psoriásica
• Cáncer (todos)

Fuentes

• Etiqueta FDA (DailyMed): Ustekinumab-aekn
• EMA: Pyzchiva
• EMA: Imuldosa